Immunogen (FRA:IMU) Short-Term Capital Lease Obligation : €4.2 Mil (As of Sep. 2023)

View and export this data going back to . Start your Free Trial

What is Immunogen Short-Term Capital Lease Obligation?

Immunogen's Short-Term Capital Lease Obligation for the quarter that ended in Sep. 2023 was €4.2 Mil.

Immunogen's quarterly Short-Term Capital Lease Obligation increased from Mar. 2023 (€3.9 Mil) to Jun. 2023 (€4.0 Mil) and increased from Jun. 2023 (€4.0 Mil) to Sep. 2023 (€4.2 Mil).

Immunogen's annual Short-Term Capital Lease Obligation increased from Dec. 2020 (€2.6 Mil) to Dec. 2021 (€3.1 Mil) and increased from Dec. 2021 (€3.1 Mil) to Dec. 2022 (€3.9 Mil).

Immunogen Short-Term Capital Lease Obligation Historical Data

The historical data trend for Immunogen's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunogen Short-Term Capital Lease Obligation Chart

Immunogen Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

2.67

2.59

3.13

3.87

Immunogen Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															4.02	3.87	3.94	4.00	4.18

Immunogen Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Immunogen Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Immunogen's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunogen (FRA:IMU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunogen Inc (FRA:IMU) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

IMGN:USA IMGN:Mexico

Address

830 Winter Street, Waltham, MA, USA, 02451

Website

https://www.immunogen.com

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent.

Immunogen (FRA:IMU) Headlines

No Headlines